US And Asian Expansion Will Unlock Pharmaceutical Market Potential

Key Takeaways

• Expansion into US and Asian markets, alongside robust order intake and backlog, is set to drive diversified and stable future revenue growth.
  
• Investment in high-margin aftermarket solutions, digitalization, and innovative R&D strengthens recurring revenues and maintains SKAN's leadership in advanced pharmaceutical manufacturing technologies.
  
• Revenues and margins face significant risk from project delays, consumable market instability, execution challenges on expansion, and potential shifts in industry procurement or pricing pressure.

Catalysts

Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.

• The significant increase in order intake (20% YoY) and a record-high order backlog reflect robust underlying pharmaceutical market growth, especially for oncology-related ADC filling lines and the ongoing shift towards injectable drugs. As backlog converts to sales in coming quarters, this supports forward revenue growth and improved earnings visibility.
  
• SKAN's accelerated expansion into the US and Asian markets, supported by a strong increase in European orders and expected huge investment wave in North America, is set to unlock new revenue streams, reduce geographic concentration risk, and enhance overall revenue growth and stability.
  
• Ongoing investments in high-margin service and aftermarket lifecycle solutions (including proprietary digital/automation capabilities gained via the Metronik acquisition and ramp-up of consumables with ABC Transfer) are poised to support higher recurring revenues and improved net margins over the medium to long term.
  
• Rising global focus on advanced biopharmaceuticals, personalized medicine, and stricter regulatory requirements are expanding the addressable market for SKAN's leading cleanroom, isolator, and contamination control technologies, offering a multi-year runway for top-line growth as pharmaceutical manufacturers increase CapEx on compliant infrastructure.
  
• The company's strengthening R&D pipeline, including modular, automation-enabled isolator systems and digital GMP compliance solutions, positions SKAN as a product and innovation leader, which will support sustainable long-term earnings growth and margin resilience.

SKAN Group Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming SKAN Group's revenue will grow by 17.1% annually over the next 3 years.
• Analysts assume that profit margins will increase from 4.9% today to 10.0% in 3 years time.
• Analysts expect earnings to reach CHF 53.2 million (and earnings per share of CHF 2.37) by about June 2029, up from CHF 16.3 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 30.3x on those 2029 earnings, down from 69.5x today. This future PE is lower than the current PE for the CH Life Sciences industry at 38.6x.
• Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 4.75%, as per the Simply Wall St company report.

Risks

• The business is highly exposed to project postponements and cancellations-as seen with delayed vaccine and GLP-1 lines-causing significant revenue shifts into future years; repeated or prolonged postponements could disrupt revenue recognition and earnings visibility, and there is "not much room" for more delays without impacting guidance.
  
• Order backlog growth is strong, but a meaningful portion (~CHF 40M) is attributed to delayed or deprioritized projects that may ultimately be cancelled or further postponed, which could lead to overstatement of forward-looking revenue and profit expectations.
  
• The market for consumables like closed vials remains lumpy and dependent on a few key customers in clinical pipeline stages; absence of broad commercialization and potential U.S. funding cuts for cell and gene therapies increase the risk of unstable or declining consumable revenues and margins.
  
• Despite ambitious expansion and acquisitions, SKAN faces ongoing execution risk, particularly in integrating and ramping up new businesses (such as ABC Transfer and Metronik), and in establishing U.S. manufacturing; delays or cost overruns here could negatively impact net margin and overall earnings.
  
• While currently benefitting from limited high-end competition, SKAN is vulnerable to shifts in industry procurement (e.g., greater adoption of single-use systems or increased price pressure from pharma customers), which may erode revenue growth and compress margins if competitors catch up, market moves toward lower-cost solutions, or cost controls are tightened.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of CHF62.5 for SKAN Group based on their expectations of its future earnings growth, profit margins and other risk factors.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CHF534.6 million, earnings will come to CHF53.2 million, and it would be trading on a PE ratio of 30.3x, assuming you use a discount rate of 4.8%.
• Given the current share price of CHF50.3, the analyst price target of CHF62.5 is 19.5% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.